{
  "ticker": "NAN",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02977405",
  "id": "02977405",
  "pages": 1,
  "price_sensitive": true,
  "date": "20250806",
  "time": "0929",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250806/pdf/06ml6psmzk9rqv.pdf",
  "summary": "- **US FDA clearance** received for next-gen **trophon3** device and **trophon2 Plus** software upgrade.  \n- **Key product advantages**:  \n  - 40% faster cycle time vs. prior generations.  \n  - Enhanced digital integration and traceability (DICOM compatibility).  \n- **Market opportunity**:  \n  - ~30,000 new devices in US hospitals/private physician markets.  \n  - ~10,000 legacy trophon EPR devices eligible for upgrade to trophon3.  \n  - ~20,000 trophon2 devices eligible for software upgrade (trophon2 Plus).  \n\n*No capital markets or trading-specific actions (e.g., raising, halts) identified.*",
  "usage": {
    "prompt_tokens": 905,
    "completion_tokens": 151,
    "total_tokens": 1056,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-05T23:36:18.403899"
}